Remission maintenance after tocilizumab dose-tapering and interruption in patients with giant cell arteritis: an open-label, 18-month, prospective, pilot study.
Carlotta NanniniLaura NiccoliStelvio SestiniIashar LaghaiAngela CoppolaFabrizio CantiniPublished in: Annals of the rheumatic diseases (2019)